Dr. Olga Uspenskaya-Cadoz and Dr. James Berry discuss PIONEER-ALS and TDP-43 research. @EverythingALS
Dr. Olga Uspenskaya-Cadoz and Dr. James Berry discuss PIONEER-ALS and TDP-43 research.  @EverythingALS
Uploaded May 2026 | Updated November 2026, 4 days ago
In this Expert Talk, Dr. Olga Uspenskaya-Cadoz and Dr. James Berry introduce PIONEER-ALS - the first vectorized antibody clinical trial targeting TDP-43 in sporadic ALS.

The session explores the science behind TDP-43 pathology in ALS and how innovative vectorized antibody approaches could potentially transform treatment strategies for sporadic ALS patients. Dr. Olga provides insight into the development of this ground-breaking trial, the rationale behind targeting TDP-43, and what this could mean for the future of ALS therapeutics.

Throughout the discussion, the speakers also highlight the importance of innovation in ALS research, patient participation in clinical trials, and the growing momentum within the ALS therapeutic pipeline.

In this talk, we cover:
• Introduction to the PIONEER-ALS clinical trial
• Understanding TDP-43 and its role in sporadic ALS
• The science behind vectorized antibody therapies
• How this approach differs from traditional ALS treatments
• The future potential of targeted ALS therapeutics
• The importance of clinical research and patient involvement

📲 Download the EverythingALS App
• Google Play: bit.ly/4nXqIYy
• App Store: bit.ly/42tPBmh

Follow EverythingALS:
► Website: everythingals.org
► X: https://x.com/everything_als
► LinkedIn: linkedin.com/company/everythingals
► Facebook: facebook.com/everythingals
► Subscribe for more Expert Talks: youtube.com/@EverythingALS

#ExpertTalk #EverythingALS #ALSResearch #ALSCommunity #ClinicalTrials #SporadicALS #TDP43 #PioneerALS #VectorizedAntibodies #Neurology #ALSTreatment #ALSInnovation #VectorY
Dr. Olga Uspenskaya-Cadoz and Dr. James Berry discuss PIONEER-ALS and TDP-43 research.Health Insurers Delay or Deny Home Ventilation. What Can Be Done? by Dr. John Hansen-Flaschen#ExpertTalk: Targeting an Endogenous Retrovirus as a Therapeutic Approach to ALSEverythingALS Radcliff Study IntroductionNeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker StudyHappy birthday Peter - July 2nd 2022Crowdsourcing: Accelerating Genetic Findings through the ALS Compute Project by Dr. John LandersVirtually bringing comfort & safety to your homeYou don’t have to be a scientist to think critically about research with Dr. Lyle OstrowDr. Richard Bedlack Introduces the ROARS HMB StudyCitizen led research in ALSOctober 15 - EverythingALS & Dr. Richard Bedlack
Everything ALS |

Dr. Olga Uspenskaya-Cadoz and Dr. James Berry discuss PIONEER-ALS and TDP-43 research.

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER